0001209191-20-028268.txt : 20200511
0001209191-20-028268.hdr.sgml : 20200511
20200511162507
ACCESSION NUMBER: 0001209191-20-028268
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200507
FILED AS OF DATE: 20200511
DATE AS OF CHANGE: 20200511
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Primiano Christopher Brett
CENTRAL INDEX KEY: 0001603510
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36167
FILM NUMBER: 20865191
MAIL ADDRESS:
STREET 1: C/O KARYOPHARM THERAPEUTICS INC.
STREET 2: 85 WELLS AVENUE, SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc.
CENTRAL INDEX KEY: 0001503802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263931704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
BUSINESS PHONE: 617-658-0600
MAIL ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-07
0
0001503802
Karyopharm Therapeutics Inc.
KPTI
0001603510
Primiano Christopher Brett
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE
NEWTON
MA
02459
0
1
0
0
EVP, CBO, GC & Secretary
Common Stock
2020-05-07
4
S
0
6714
19.6168
D
4649
D
Common Stock
2020-05-07
4
M
0
2946
6.54
A
7595
D
Common Stock
2020-05-07
4
S
0
2946
20.00
D
4649
D
Stock Option (right to buy)
6.54
2020-05-07
4
M
0
2946
0.00
D
2026-01-14
Common Stock
2946
10054
D
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.37 to $20.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Includes 996 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan.
This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.
/s/ Christopher B. Primiano
2020-05-11